These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 31640815)

  • 1. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
    J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
    Takeda R; Asada S; Park SJ; Yokoyama A; Becker HJ; Kanai A; Visconte V; Hershberger C; Hayashi Y; Yonezawa T; Tamura M; Fukushima T; Tanaka Y; Fukuyama T; Matsumoto A; Yamasaki S; Nakai K; Yamazaki S; Inaba T; Shibata T; Inoue D; Honda H; Goyama S; Maciejewski JP; Kitamura T
    Blood; 2020 Oct; 136(14):1670-1684. PubMed ID: 32492700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
    Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
    Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.
    Tsai SC; Shih LY; Liang ST; Huang YJ; Kuo MC; Huang CF; Shih YS; Lin TH; Chiu MC; Liang DC
    Clin Cancer Res; 2015 Aug; 21(15):3541-51. PubMed ID: 25840971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
    Zhao W; Zhang C; Li Y; Li Y; Liu Y; Sun X; Liu M; Shao R
    Hematology; 2022 Dec; 27(1):367-378. PubMed ID: 35306971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Yang L; Wei X; Gong Y
    Cancer Med; 2024 Jan; 13(1):e6871. PubMed ID: 38146893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of ASXL1 mutation in myeloid malignancies].
    Sheng MY; Zhou Y; Xu MJ; Yang FC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
    Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
    Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.
    Paschka P; Schlenk RF; Gaidzik VI; Herzig JK; Aulitzky T; Bullinger L; Späth D; Teleanu V; Kündgen A; Köhne CH; Brossart P; Held G; Horst HA; Ringhoffer M; Götze K; Nachbaur D; Kindler T; Heuser M; Thol F; Ganser A; Döhner H; Döhner K
    Haematologica; 2015 Mar; 100(3):324-30. PubMed ID: 25596267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.
    Kuo MC; Liang DC; Huang CF; Shih YS; Wu JH; Lin TL; Shih LY
    Leukemia; 2009 Aug; 23(8):1426-31. PubMed ID: 19282830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation by ASXL1 in myeloid malignancies.
    Yang FC; Agosto-Peña J
    Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
    You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
    Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia.
    Binder M; Carr RM; Lasho TL; Finke CM; Mangaonkar AA; Pin CL; Berger KR; Mazzone A; Potluri S; Ordog T; Robertson KD; Marks DL; Fernandez-Zapico ME; Gaspar-Maia A; Patnaik MM
    Nat Commun; 2022 Mar; 13(1):1434. PubMed ID: 35301312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model.
    Hsu YC; Chiu YC; Lin CC; Kuo YY; Hou HA; Tzeng YS; Kao CJ; Chuang PH; Tseng MH; Hsiao TH; Chou WC; Tien HF
    J Hematol Oncol; 2017 Jul; 10(1):139. PubMed ID: 28697759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran.
    Parsa-Kondelaji M; Ayatollahi H; Rostami M; Sheikhi M; Barzegar F; Afzalaghaee M; Moradi E; Sadeghian MH; Momtazi-Borojeni AA
    J Cell Mol Med; 2022 Jul; 26(13):3797-3801. PubMed ID: 35692075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9-mediated ASXL1 mutations in U937 cells disrupt myeloid differentiation.
    Wu ZJ; Zhao X; Banaszak LG; Gutierrez-Rodrigues F; Keyvanfar K; Gao SG; Quinones Raffo D; Kajigaya S; Young NS
    Int J Oncol; 2018 Apr; 52(4):1209-1223. PubMed ID: 29532865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic SETBP1 mutations in myeloid neoplasms.
    Makishima H
    Int J Hematol; 2017 Jun; 105(6):732-742. PubMed ID: 28447248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
    Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
    Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
    Nagase R; Inoue D; Pastore A; Fujino T; Hou HA; Yamasaki N; Goyama S; Saika M; Kanai A; Sera Y; Horikawa S; Ota Y; Asada S; Hayashi Y; Kawabata KC; Takeda R; Tien HF; Honda H; Abdel-Wahab O; Kitamura T
    J Exp Med; 2018 Jun; 215(6):1729-1747. PubMed ID: 29643185
    [No Abstract]   [Full Text] [Related]  

  • 20. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
    Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
    Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.